Oxidative and Inflammatory Pathways in Parkinsonâ€s

Neurochemical Research

34, 55-65

DOI: 10.1007/s11064-008-9656-2

Citation Report

#	Article	IF	Citations
1	Botanical Phenolics and Brain Health. NeuroMolecular Medicine, 2008, 10, 259-274.	1.8	189
2	Importance of the non-selective cation channel TRPV1 for microglial reactive oxygen species generation. Journal of Neuroimmunology, 2009, 216, 118-121.	1.1	61
3	Recent advances in our understanding of neurodegeneration. Journal of Neural Transmission, 2009, 116, 1111-1162.	1.4	235
4	Oxidative and Inflammatory Pathways in Parkinsonâ€™s Disease. Neurochemical Research, 2009, 34, 55-65.	1.6	280
6	Interferon-Î³ deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience, 2009, 164, 1894-1906.	1.1	50
8	Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. NeuroToxicology, 2009, 30, 1008-1018.	1.4	30
9	Neurovascular Coupling in Parkinson's Disease Patients: Effects of Dementia and Acetylcholinesterase Inhibitor Treatment. Journal of Alzheimer's Disease, 2010, 22, 415-421.	1.2	24
10	MMHD [(S,E)-2-Methyl-1-(2-methylthiazol-4-yl) hexa-1,5-dien-ol], a Novel Synthetic Compound Derived From Epothilone, Suppresses Nuclear Factor-ÎºBâ€“Mediated Cytokine Expression in Lipopolysaccharide-Stimulated BV-2 Microglia. Journal of Pharmacological Sciences, 2010, 112, 158-166.	1.1	14
11	Nitric Oxide Signaling in Brain Function, Dysfunction, and Dementia. Neuroscientist, 2010, 16, 435-452.	2.6	374
12	Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinsonâ€™s, Huntingtonâ€™s, Alzheimerâ€™s, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology, 2010, 84, 825-889.	1.9	330
13	Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases. Molecular Neurobiology, 2010, 41, 375-383.	1.9	283
14	Ion channels in monocytes and microglia / brain macrophages: Promising therapeutic targets for neurological diseases. Journal of Neuroimmunology, 2010, 224, 51-55.	1.1	52
15	Stimulus-dependent requirement of ion channels for microglial NADPH oxidase-mediated production of reactive oxygen species. Journal of Neuroimmunology, 2010, 225, 190-194.	1.1	28
16	Basic mechanisms of neurodegeneration: a critical update. Journal of Cellular and Molecular Medicine, 2010, 14, 457-487.	1.6	330
17	Neuroprotective effects of hydrogen sulfide on Parkinsonâ€™s disease rat models. Aging Cell, 2010, 9, 135-146.	3.0	311
18	The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. Free Radical Research, 2010, 44, 1304-1316.	1.5	39
19	Urban Air Pollution Targets the Dorsal Vagal Complex and Dark Chocolate Offers Neuroprotection. International Journal of Toxicology, 2010, 29, 604-615.	0.6	38
20	Abasic sites preferentially form at regions undergoing DNA replication. FASEB Journal, 2010, 24, 3674-3680.	0.2	41

#	Article	IF	Citations
21	Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinsonâ€™s Disease. Journal of Immunology, 2010, 185, 1230-1237.	0.4	136
22	Resveratrol Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity through Its Anti-Inflammatory Actions. Molecular Pharmacology, 2010, 78, 466-477.	1.0	162
23	Genetic Polymorphism and Susceptibility to Pesticides. , 2010, , 525-549.		0
24	Biomarkers of Cell Damage Induced by Oxidative Stress in Parkinsons Disease and Related Models. Central Nervous System Agents in Medicinal Chemistry, 2010, 10, 278-286.	0.5	15
25	Antioxidative and Anti-Inflammatory Protection from Carnosine in the Striatum of MPTP-Treated Mice. Journal of Agricultural and Food Chemistry, 2010, 58, 11510-11516.	2.4	84
26	Differential Proteome of the Striatum from Hemiparkinsonian Rats Displays Vivid Structural Remodeling Processes. Journal of Proteome Research, 2010, 9, 4671-4687.	1.8	42
27	Modeling neuroinflammatory pathogenesis of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 113-132.	0.9	83
28	Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential. Antioxidants and Redox Signaling, 2010, 13, 877-918.	2.5	460
29	Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Antioxidants and Redox Signaling, 2010, 12, 125-169.	2.5	377
30	Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochemistry International, 2010, 56, 229-244.	1.9	54
31	Pathological roles of MAPK signaling pathways in human diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 396-405.	1.8	1,876
32	Alpha-synuclein, lipids and Parkinsonâ€™s disease. Progress in Lipid Research, 2010, 49, 420-428.	5.3	180
33	Paraquat. , 2010, , 1771-1827.		23
34	Anti-inflammatory activity of natural dietary flavonoids. Food and Function, 2010, 1, 15.	2.1	448
35	Plasma level of malondialdehyde in the cases of acute paraquat intoxication. Clinical Toxicology, 2010, 48, 149-152.	0.8	21
36	Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease. Alzheimer's Research and Therapy, 2011, 3, 21.	3.0	17
37	Oxidative stress in zinc-induced dopaminergic neurodegeneration: Implications of superoxide dismutase and heme oxygenase-1. Free Radical Research, 2011, 45, 1207-1222.	1.5	27
38	Oxidative Stress and Free Radical Damage in Neurology. , 2011, , .		26

#	Article	IF	Citations
39	Dual Functionality of Myeloperoxidase in Rotenone-Exposed Brain-Resident Immune Cells. American Journal of Pathology, 2011, 179, 964-979.	1.9	33
40	Protective effect of Chrysanthemum indicum Linne against 1-methyl-4-phenylpridinium ion and lipopolysaccharide-induced cytotoxicity in cellular model of Parkinsonâ€™s disease. Food and Chemical Toxicology, 2011, 49, 963-973.	1.8	44
41	Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation. Journal of Immunology, 2011, 187, 6508-6517.	0.4	106
42	Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of Î±-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity. Neuroscience Research, 2011, 71, 387-395.	1.0	36
43	Protein kinase C mediates peroxynitrite toxicity to oligodendrocytes. Molecular and Cellular Neurosciences, 2011, 48, 62-71.	1.0	15
44	Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology, 2011, 60, 963-974.	2.0	113
45	BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience, 2011, 180, 293-304.	1.1	9
46	Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroscience, 2011, 182, 203-207.	1.1	7
47	Redox Control of the Survival of Healthy and Diseased Cells. Antioxidants and Redox Signaling, 2011, 15, 2867-2908.	2.5	145
48	Features of Microglia and Neuroinflammation Relevant to Environmental Exposure and Neurotoxicity. International Journal of Environmental Research and Public Health, 2011, 8, 2980-3018.	1.2	242
49	Gastrodin Inhibits Expression of Inducible NO Synthase, Cyclooxygenase-2 and Proinflammatory Cytokines in Cultured LPS-Stimulated Microglia via MAPK Pathways. PLoS ONE, 2011, 6, e21891.	1.1	189
50	The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease. Current Pharmaceutical Design, 2011, 17, 489-507.	0.9	75
51	Botanical Phenolics and Neurodegeneration. Oxidative Stress and Disease, 2011, , 315-332.	0.3	2
52	Neuroprotective Effect of Kaempferol against a 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease. Biological and Pharmaceutical Bulletin, 2011, 34, 1291-1296.	0.6	125
53	Neonatal exposure to lipopolysaccharide enhances vulnerability of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life. Neurobiology of Disease, 2011, 44, 304-316.	2.1	41
54	Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. ACS Symposium Series, 2011, , 255-288.	0.5	19
55	Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain. Journal of Neural Transmission, 2011, 118, 433-444.	1.4	16
56	ä¸€æ°§åŒ–æ°®åœ¨ç¥žç»éŒ€è¡Œæ€§ç–¾ç—…ä¸çš„ä½œç”¨ : éžç±»å›°é†‡æ€§ŠŠç‚Žè¯çš„æ²»ç——å‰æ™¯. Neuroscience Bulletin,	1.5	20

#	Article	IF	Citations
57	Dopamine and Paraquat Enhance Î±-Synuclein-Induced Alterations in Membrane Conductance. Neurotoxicity Research, 2011, 20, 387-401.	1.3	16
58	Urinary 8â€OHdG elevations in a partial lesion rat model of parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. Journal of Cellular Physiology, 2011, 226, 1390-1398.	2.0	26
59	Amyloid-Î²-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. Journal of Cellular Physiology, 2011, 226, 3295-3302.	2.0	97
60	Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems. Glia, 2011, 59, 1551-1566.	2.5	51
61	Kaempferol Attenuates 4-Hydroxynonenal-Induced Apoptosis in PC12 Cells by Directly Inhibiting NADPH Oxidase. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 747-754.	1.3	44
62	Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases. Current Pharmaceutical Design, 2011, 17, 3418-3433.	0.9	62
63	MPTP-Induced Neuroinflammation Increases the Expression of Pro-Inflammatory Cytokines and Their Receptors in Mouse Brain. NeuroImmunoModulation, 2011, 18, 79-88.	0.9	92
64	Does 1-(R)-aminoindan Possess Neuroprotective Properties Against Experimental Parkinson's Disease?. Antioxidants and Redox Signaling, 2011, 14, 767-775.	2.5	9
65	Neurobiology of Vascular Dementia. Journal of Aging Research, 2011, 2011, 1-11.	0.4	22
66	Protective effect of methanolic extract of Garcinia indica fruits in 6-OHDA rat model of Parkinsonâ€²s disease. Indian Journal of Pharmacology, 2012, 44, 683.	0.4	24
67	Neuroprotective Effects of San-Huang-Xie-Xin-Tang in the MPP⁺/MPTP Models of Parkinsonâ€™s DiseaseIn VitroandIn Vivo. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	33
68	The Protease Omi Cleaves the Mitogen-Activated Protein Kinase Kinase MEK1 to Inhibit Microglial Activation. Science Signaling, 2012, 5, ra61.	1.6	24
69	Redox Regulation of Protein Function via Cysteine S-Nitrosylation and Its Relevance to Neurodegenerative Diseases. International Journal of Cell Biology, 2012, 2012, 1-9.	1.0	46
70	Dysregulation of Glutathione Homeostasis in Neurodegenerative Diseases. Nutrients, 2012, 4, 1399-1440.	1.7	278
71	Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease. Current Pharmaceutical Design, 2012, 18, 200-208.	0.9	55
72	Acacetin Protects Dopaminergic Cells against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Neuroinflammation <i>in Vitro</i> and <i>in Vivo</i>. Biological and Pharmaceutical Bulletin, 2012, 35, 1287-1294.	0.6	72
73	Chronic exposure to imidacloprid induces inflammation and oxidative stress in the liver & central nervous system of rats. Pesticide Biochemistry and Physiology, 2012, 104, 58-64.	1.6	123
74	Oxidative stress and inflammation biomarkers in the blood of patients with Huntingtonâ€™s disease. Neurological Research, 2012, 34, 721-724.	0.6	74

#	Article	IF	Citations
75	NADPH Oxidase 1 Mediates Î±-Synucleinopathy in Parkinson's Disease. Journal of Neuroscience, 2012, 32, 14465-14477.	1.7	79
76	Biomedical Applications of Metal Oxide Nanoparticles. , 2012, , 57-100.		38
77	Neuroprotective effects of tert-butylhydroquinone on paraquat-induced dopaminergic cell degeneration in C57BL/6 mice and in PC12 cells. Archives of Toxicology, 2012, 86, 1729-1740.	1.9	38
78	The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6. Chemico-Biological Interactions, 2012, 200, 73-83.	1.7	19
79	A self-propelling cycle mediated by reactive oxide species and nitric oxide exists in LPS-activated microglia. Neurochemistry International, 2012, 61, 1220-1230.	1.9	29
80	Interferon-Î³ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiology of Aging, 2012, 33, 1411-1426.	1.5	74
81	Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenaseâ€1 and brainâ€derived neurotrophic factor. British Journal of Pharmacology, 2012, 166, 1151-1168.	2.7	77
82	Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neuroscience Letters, 2012, 506, 175-179.	1.0	44
83	Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress. Brain Research Bulletin, 2012, 89, 92-96.	1.4	62
84	Physical activity and environmental enrichment regulate the generation of neural precursors in the adult mouse substantia nigra in a dopamine-dependent manner. BMC Neuroscience, 2012, 13, 132.	0.8	46
85	Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinsonâ€™s disease: Role of regulatory T cells. Brain, Behavior, and Immunity, 2012, 26, 1322-1330.	2.0	64
86	Tat-Frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson's disease. Biochimie, 2012, 94, 2448-2456.	1.3	17
87	Role of some functional lipids in preventing diseases and promoting health. Journal of King Saud University - Science, 2012, 24, 319-329.	1.6	46
88	Coenzyme Q10 deficiency in patients with Parkinson's disease. Journal of the Neurological Sciences, 2012, 318, 72-75.	0.3	80
89	Rodent Models and Contemporary Molecular Techniques: Notable Feats yet Incomplete Explanations of Parkinsonâ€™s Disease Pathogenesis. Molecular Neurobiology, 2012, 46, 495-512.	1.9	28
90	Cypermethrin Alters the Expression Profile of mRNAs in the Adult Rat Striatum: A Putative Mechanism of Postnatal Pre-exposure Followed by Adulthood Re-exposure-Enhanced Neurodegeneration. Neurotoxicity Research, 2012, 22, 321-334.	1.3	16
91	Animal Models of Movement Disorders. Neuromethods, 2012, , .	0.2	1
92	Physiological Antioxidative Network of the Bilirubin System in Aging and Age-Related Diseases. Frontiers in Pharmacology, 2012, 3, 45.	1.6	28

#	Article	IF	Citations
93	Involvement of Prx3, a Drosophila ortholog of the thiol-dependent peroxidase PRDX3, in age-dependent oxidative stress resistance. Biomedical Research, 2012, 33, 319-322.	0.3	6
94	Tauroursodeoxycholic Acid Prevents MPTP-Induced Dopaminergic Cell Death in a Mouse Model of Parkinsonâ€™s Disease. Molecular Neurobiology, 2012, 46, 475-486.	1.9	119
95	Glutathione S-Transferase pi Mediates MPTP-Induced c-Jun N-Terminal Kinase Activation in the Nigrostriatal Pathway. Molecular Neurobiology, 2012, 45, 466-477.	1.9	46
96	ATM kinase inhibition in glial cells activates the innate immune response and causes neurodegeneration in Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E656-64.	3.3	120
97	NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacology, 2012, 20, 159-167.	1.9	7
98	Antioxidant and anti-inflammatory properties of Dichondra repens Forst. and its reference compounds. Food Chemistry, 2012, 132, 1010-1018.	4.2	21
99	Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: Similarity with paraquat neurotoxicity. Brain Research, 2012, 1438, 48-64.	1.1	53
100	Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Research, 2012, 1451, 110-116.	1.1	54
101	Tenuigenin Protects Dopaminergic Neurons from Inflammationâ€Mediated Damage Induced by the Lipopolysaccharide. CNS Neuroscience and Therapeutics, 2012, 18, 584-590.	1.9	37
102	Antioxidant and Anti-Apoptotic Activity of Vasoactive Intestinal Peptide (VIP) Against 6-Hydroxy Dopamine Toxicity in the Rat Corpus Striatum. Journal of Molecular Neuroscience, 2012, 46, 51-57.	1.1	37
103	Melatonin as a Neuroprotective Agent in the Rodent Models of Parkinsonâ€™s Disease: Is it All Set to Irrefutable Clinical Translation?. Molecular Neurobiology, 2012, 45, 186-199.	1.9	63
104	Intranigral lipopolysaccharide administration induced behavioral deficits and oxidative stress damage in laboratory rats: Relevance for Parkinson's disease. Behavioural Brain Research, 2013, 253, 25-31.	1.2	25
105	Microglial Activation and Antioxidant Responses Induced by the Parkinsonâ€™s Disease Protein Î±-Synuclein. Journal of NeuroImmune Pharmacology, 2013, 8, 94-117.	2.1	145
106	Antioxidant and anti-inflammatory properties of taiwanese yam (Dioscorea japonica Thunb. var.) Tj ETQq1 1 0.784314 rgBT /Overlock	4.2	67
107	Neuroimmunological Processes in Parkinson's Disease and their Relation to Î±-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity. ASN Neuro, 2013, 5, AN20120066.	1.5	197
108	Anti-apoptotic and Anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's Rat model. Journal of Nutritional Biochemistry, 2013, 24, 680-687.	1.9	109
109	Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease. Pharmacological Reports, 2013, 65, 44-49.	1.5	28
110	Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochemical Pharmacology, 2013, 86, 759-769.	2.0	99

#	Article	IF	Citations
111	Neonatal Systemic Exposure to Lipopolysaccharide Enhances Susceptibility of Nigrostriatal Dopaminergic Neurons to Rotenone Neurotoxicity in Later Life. Developmental Neuroscience, 2013, 35, 155-171.	1.0	35
112	Genetics and iron in the systems biology of Parkinsonâ€™s disease and some related disorders. Neurochemistry International, 2013, 62, 637-652.	1.9	56
114	Aberrant Protein S-Nitrosylation in Neurodegenerative Diseases. Neuron, 2013, 78, 596-614.	3.8	304
115	Psoriasis is associated with an increased risk of parkinsonism: A population-based 5-year follow-up study. Journal of the American Academy of Dermatology, 2013, 68, 992-999.	0.6	33
116	Antioxidant effect of Spirulina (Arthrospira) maxima in a neurotoxic model caused by 6-OHDA in the rat striatum. Journal of Neural Transmission, 2013, 120, 1179-1189.	1.4	39
117	Behavioral and Neurochemical Effects of Alpha-Lipoic Acid in the Model of Parkinsonâ€™s Disease Induced by Unilateral Stereotaxic Injection of 6-Ohda in Rat. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	25
118	Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation. Immunopharmacology and Immunotoxicology, 2013, 35, 581-593.	1.1	9
119	Retinal Nerve Fiber Layer Thickness in Parkinson Disease. Journal of Neuro-Ophthalmology, 2013, 33, 62-65.	0.4	93
121	Resveratrol Confers Protection against Rotenone-Induced Neurotoxicity by Modulating Myeloperoxidase Levels in Glial Cells. PLoS ONE, 2013, 8, e60654.	1.1	45
122	Rotenone Directly Induces BV2 Cell Activation via the p38 MAPK Pathway. PLoS ONE, 2013, 8, e72046.	1.1	65
123	Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration. Journal of Neurorestoratology, 0, , 47.	1.1	7
124	Rotenone-induced nigrostriatal toxicity is reduced by methylene blue. Journal of Neurorestoratology, 0, , 65.	1.1	13
125	Neuroprotective Effects of Cuscutae Semen in a Mouse Model of Parkinsonâ€™s Disease. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-11.	0.5	14
126	Correlation between Serum RANTES Levels and the Severity of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-4.	1.9	56
127	Apocynin, a Low Molecular Oral Treatment for Neurodegenerative Disease. BioMed Research International, 2014, 2014, 1-6.	0.9	45
128	The Functional Role of MnSOD as a Biomarker of Human Diseases and Therapeutic Potential of a New Isoform of a Human Recombinant MnSOD. BioMed Research International, 2014, 2014, 1-11.	0.9	33
129	Resveratrol Partially Prevents Rotenone-Induced Neurotoxicity in Dopaminergic SH-SY5Y Cells through Induction of Heme Oxygenase-1 Dependent Autophagy. International Journal of Molecular Sciences, 2014, 15, 1625-1646.	1.8	144
130	Tat-Fused Recombinant Human SAG Prevents Dopaminergic Neurodegeneration in a MPTP-Induced Parkinsonâ€™s Disease Model. Molecules and Cells, 2014, 37, 226-233.	1.0	4

#	Article	IF	Citations
131	Cypermethrin alters the status of oxidative stress in the peripheral blood: relevance to Parkinsonism. Journal of Physiology and Biochemistry, 2014, 70, 915-924.	1.3	15
132	Fasciculation and elongation protein zetaâ€1 (<scp>FEZ</scp>1) expression in reactive astrocytes in a rat model of <scp>P</scp>arkinson's disease. Neuropathology and Applied Neurobiology, 2014, 40, 164-176.	1.8	10
134	Does Restraining Nitric Oxide Biosynthesis Rescue from Toxins-Induced Parkinsonism and Sporadic Parkinson's Disease?. Molecular Neurobiology, 2014, 49, 262-275.	1.9	21
135	Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic Neurodegeneration. Molecular Neurobiology, 2014, 49, 1153-1165.	1.9	67
136	Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cellular and Molecular Life Sciences, 2014, 71, 1607-1622.	2.4	124
137	Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 82-87.	1.1	108
138	Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2014, 21, 451-455.	0.8	16
139	Polygalasaponin F inhibits secretion of inflammatory cytokines via NF-Î°B pathway regulation. Journal of Asian Natural Products Research, 2014, 16, 865-875.	0.7	9
140	6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinsonâ€™s disease: respirometric, histological, and behavioral analyses. Journal of Neural Transmission, 2014, 121, 1245-1257.	1.4	30
141	Oral Supplements of Aqueous Extract of Tomato Seeds Alleviate Motor Abnormality, Oxidative Impairments and Neurotoxicity Induced by Rotenone in Mice: Relevance to Parkinsonâ€™s Disease. Neurochemical Research, 2014, 39, 1382-1394.	1.6	45
142	Increased Risk of Parkinson Disease Following a Diagnosis of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study. American Journal of Ophthalmology, 2014, 157, 464-469.e1.	1.7	27
143	5â€Sâ€cysteinyldopamine neurotoxicity: Influence on the expression of Î±â€synuclein and ERp57 in cellular and animal models of Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 347-358.	1.3	31
144	Proteomic analysis of carbonylated proteins in the monkey substantia nigra after ischemia-reperfusion. Free Radical Research, 2014, 48, 694-705.	1.5	15
145	Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia. Molecular Medicine Reports, 2015, 12, 1002-1008.	1.1	34
146	<scp>TGF</scp>Î²1 inhibits <scp>IFN</scp>Î³â€mediated microglia activation and protects <scp>mDA</scp> neurons from <scp>IFN</scp>Î³â€driven neurotoxicity. Journal of Neurochemistry, 2015, 134, 125-134.	2.1	39
147	Plasma Prolidase Activity and Oxidative Stress in Patients with Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-6.	0.6	17
148	A 5-Year Follow-up Study on the Relationship between Obstructive Sleep Apnea and Parkinson Disease. Journal of Clinical Sleep Medicine, 2015, 11, 1403-1408.	1.4	43
149	Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model. International Journal of Molecular Medicine, 2015, 36, 1369-1376.	1.8	72

#	Article	IF	Citations
150	Angiotensin II Triggers Apoptosis Via Enhancement of NADPH Oxidase-Dependent Oxidative Stress in a Dopaminergic Neuronal Cell Line. Neurochemical Research, 2015, 40, 854-863.	1.6	26
151	Nesfatin-1 antagonized rotenone-induced neurotoxicity in MES23.5 dopaminergic cells. Peptides, 2015, 69, 109-114.	1.2	20
152	Neuroprotective effect of Valeriana wallichii rhizome extract against the neurotoxin MPTP in C57BL/6 mice. NeuroToxicology, 2015, 51, 172-183.	1.4	24
153	Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system. BMC Complementary and Alternative Medicine, 2015, 15, 151.	3.7	23
154	Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease. Journal of the Neurological Sciences, 2015, 348, 142-152.	0.3	59
155	Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis. Neurochemistry International, 2015, 80, 79-86.	1.9	65
156	Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson's disease in CATH.a cells. Neurotoxicology and Teratology, 2015, 47, 16-24.	1.2	35
157	Rotenone Induction of Hydrogen Peroxide Inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E Pathways, Leading to Neuronal Apoptosis. Toxicological Sciences, 2015, 143, 81-96.	1.4	90
158	Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System. Experimental Neurobiology, 2016, 25, 147-155.	0.7	13
159	Acute paraquat exposure impairs colonic motility by selectively attenuating nitrergic signalling in the mouse. Autonomic Neuroscience: Basic and Clinical, 2016, 195, 8-15.	1.4	5
160	Downregulation of miR-384-5p attenuates rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through inhibiting endoplasmic reticulum stress. American Journal of Physiology - Cell Physiology, 2016, 310, C755-C763.	2.1	33
161	Phytochemicals as future drugs for Parkinsonâ€™s disease: a comprehensive review. Reviews in the Neurosciences, 2016, 27, 651-668.	1.4	66
162	Comparison of serum trace elements and antioxidant levels in terrier dogs with or without behavior problems. Applied Animal Behaviour Science, 2016, 180, 87-92.	0.8	7
163	<scp>l</scp>-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?. Synapse, 2016, 70, 479-500.	0.6	53
164	Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity. Neuroscience, 2016, 337, 218-223.	1.1	7
165	Vitamin K2 suppresses rotenone-induced microglial activation in vitro. Acta Pharmacologica Sinica, 2016, 37, 1178-1189.	2.8	39
166	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. , 2016, , .		10
167	Neuroprotective Effect ofCoptis chinensisin MPP+ and MPTP-Induced Parkinsonâ€™s Disease Models. The American Journal of Chinese Medicine, 2016, 44, 907-925.	1.5	31

#	Article	IF	Citations
168	Neuro-protective effects of Ligustri Fructus by suppression of oxidative stress in mouse model of Parkinsonâ€™s disease. Oriental Pharmacy and Experimental Medicine, 2016, 16, 123-129.	1.2	1
169	A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Archives of Toxicology, 2016, 90, 2725-2743.	1.9	90
170	Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinsonâ€™s Disease Model. Molecular Neurobiology, 2016, 53, 3326-3337.	1.9	33
171	Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions. Molecular Neurobiology, 2016, 53, 2761-2777.	1.9	29
172	Neuronal Nitric Oxide Synthase Negatively Regulates Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration. Molecular Neurobiology, 2017, 54, 2685-2696.	1.9	15
173	Proteomic studies associated with Parkinsonâ€™s disease. Expert Review of Proteomics, 2017, 14, 193-209.	1.3	13
174	Bee venom for the treatment of Parkinsonâ€™s disease: How far is it possible?. Biomedicine and Pharmacotherapy, 2017, 91, 295-302.	2.5	23
175	Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2171-2181.	1.8	54
176	The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. European Journal of Pharmacology, 2017, 817, 86-95.	1.7	155
177	Celastrol Attenuates Cadmiumâ€Induced Neuronal Apoptosis via Inhibiting Ca²⁺â€CaMKIIâ€Dependent Akt/mTOR Pathway. Journal of Cellular Physiology, 2017, 232, 2145-2157.	2.0	34
178	Impairment of dynamic thiolâ€“disulphide homeostasis in patients with idiopathic Parkinsonâ€™s disease and its relationship with clinical stage of disease. Clinical Neurology and Neurosurgery, 2017, 153, 50-55.	0.6	20
179	Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic l-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells. Neurotoxicity Research, 2017, 31, 334-347.	1.3	5
180	Shatavarin IV elicits lifespan extension and alleviates Parkinsonism inCaenorhabditis elegans. Free Radical Research, 2017, 51, 954-969.	1.5	29
181	Paraquat and MPTP induce neurodegeneration and alteration in the expression profile of microRNAs: the role of transcription factor Nrf2. Npj Parkinson's Disease, 2017, 3, 31.	2.5	27
182	Endoplasmic Reticulum Stress and NF-ÎºB Pathway in Salidroside Mediated Neuroprotection: Potential of Salidroside in Neurodegenerative Diseases. The American Journal of Chinese Medicine, 2017, 45, 1459-1475.	1.5	19
183	Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports, 2017, 7, 9459.	1.6	45
184	Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats. Neuroscience Letters, 2017, 657, 45-52.	1.0	30
185	Pathological Î±-synuclein exacerbates the progression of Parkinsonâ€™s disease through microglial activation. Toxicology Letters, 2017, 265, 30-37.	0.4	119

#	Article	IF	Citations
186	Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease. Stem Cells Translational Medicine, 2017, 6, 634-646.	1.6	152
187	The state of systemic oxidative stress during Parkinsonâ€™s disease. Neurochemical Journal, 2017, 11, 340-345.	0.2	10
188	Age and Chronicity of Administration Dramatically Influenced the Impact of Low Dose Paraquat Exposure on Behavior and Hypothalamic-Pituitary-Adrenal Activity. Frontiers in Aging Neuroscience, 2017, 9, 222.	1.7	14
189	No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biological Reviews, 2018, 93, 1518-1557.	4.7	92
190	The metabolism of imidacloprid by aldehyde oxidase contributes to its clastogenic effect in New Zealand rabbits. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2018, 829-830, 26-32.	0.9	27
191	Pesticide use in agriculture and Parkinsonâ€™s disease in the AGRICAN cohort study. International Journal of Epidemiology, 2018, 47, 299-310.	0.9	101
192	3D tissue engineering, an emerging technique for pharmaceutical research. Acta Pharmaceutica Sinica B, 2018, 8, 756-766.	5.7	49
193	Minimally Toxic Dose of Lipopolysaccharide and Î±-Synuclein Oligomer Elicit Synergistic Dopaminergic Neurodegeneration: Role and Mechanism of Microglial NOX2 Activation. Molecular Neurobiology, 2018, 55, 619-632.	1.9	27
194	Carnosic Acid Induces Anti-Inflammatory Effects in Paraquat-Treated SH-SY5Y Cells Through a Mechanism Involving a Crosstalk Between the Nrf2/HO-1 Axis and NF-ÎºB. Molecular Neurobiology, 2018, 55, 890-897.	1.9	43
195	Gutâ€“brain and brainâ€“gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet. Nutritional Neuroscience, 2018, 21, 391-402.	1.5	68
196	Updates on immunity and inflammation in Parkinson disease pathology. Journal of Neuroscience Research, 2018, 96, 379-390.	1.3	86
197	Neurotherapeutic Effects of Bee Venom in a Rotenone-Induced Mouse Model of Parkinsonâ€™s Disease. Neurophysiology, 2018, 50, 445-455.	0.2	9
198	Research Paper: Neuroprotective Effect of Quercetin Nanocrystal in a 6-Hydroxydopamine Model of Parkinson Disease: Biochemical and Behavioral Evidence. Basic and Clinical Neuroscience, 2018, 9, 317-324.	0.3	54
199	Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinsonâ€™s Disease. Mediators of Inflammation, 2018, 2018, 1-8.	1.4	7
200	Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?. Journal of Neuroinflammation, 2018, 15, 328.	3.1	13
201	Parkinsonâ€™s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects. Current Treatment Options in Gastroenterology, 2018, 16, 489-510.	0.3	19
202	Silymarin recovers 6-hydroxydopamine-induced motor deficits in mice. Food and Chemical Toxicology, 2018, 118, 549-556.	1.8	6
203	Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-9.	1.9	14

#	Article	IF	Citations
204	Modulation of M1/M2 polarization by capsaicin contributes to the survival of dopaminergic neurons in the lipopolysaccharide-lesioned substantia nigra in vivo. Experimental and Molecular Medicine, 2018, 50, 1-14.	3.2	85
205	Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Frontiers in Molecular Neuroscience, 2018, 11, 165.	1.4	62
206	Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 1689.	1.8	235
207	A nutritional approach to microbiota in Parkinsonâ€™s disease. Bioscience of Microbiota, Food and Health, 2019, 38, 115-127.	0.8	32
208	Nonpharmacological Modulation of Chronic Inflammation in Parkinsonâ€™s Disease: Role of Diet Interventions. Parkinson's Disease, 2019, 2019, 1-12.	0.6	13
209	Dietary Polyphenolsâ€”Important Non-Nutrients in the Prevention of Chronic Noncommunicable Diseases. A Systematic Review. Nutrients, 2019, 11, 1039.	1.7	147
210	Ferroptosis and Its Role in Diverse Brain Diseases. Molecular Neurobiology, 2019, 56, 4880-4893.	1.9	319
211	The relationship between obstructive sleep apnea and Parkinsonâ€™s disease: a systematic review and meta-analysis. Neurological Sciences, 2020, 41, 1153-1162.	0.9	30
212	Quantum dot conjugated saporin activates microglia and induces selective substantia nigra degeneration. NeuroToxicology, 2020, 76, 153-161.	1.4	3
214	INVESTIGATION OF THE NEUROPROTECTIVE EFFECT OF LINAGLIPTIN AND CELIPROLOL IN RESERPINE-INDUCED OROFACIAL DYSKINESIA AND ROTENONE-INDUCED NEURODEGENERATION IN RATS. International Journal of Current Pharmaceutical Research, 0, , 63-71.	0.2	0
215	Histomorphological evaluations on the frontal cortex extrapyramidal cell layer following administration of N-Acetyl cysteine in aluminum induced neurodegeneration rat model. Metabolic Brain Disease, 2020, 35, 829-839.	1.4	16
216	Bioactive Polyphenols and Neuromodulation: Molecular Mechanisms in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 2564.	1.8	63
217	Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol. CNS and Neurological Disorders - Drug Targets, 2021, 20, 327-342.	0.8	27
218	Inflammatory Mechanisms in Parkinsonâ€™s Disease: From Pathogenesis to Targeted Therapies. Neuroscientist, 2022, 28, 485-506.	2.6	14
219	REST Protects Dopaminergic Neurons from Mitochondrial and Î±-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model. Journal of Neuroscience, 2021, 41, 3731-3746.	1.7	15
220	Fyn Kinase-Mediated PKCÎ´ Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 631375.	1.6	4
221	A unique understanding of traditional medicine of pomegranate, Punica granatum L. and its current research status. Journal of Ethnopharmacology, 2021, 271, 113877.	2.0	54
222	PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinsonâ€™s Disease. Molecules, 2021, 26, 3329.	1.7	5

#	Article	IF	Citations
223	Long-term exposure to 2-amino-3-methylimidazo[4,5-f]quinoline can trigger a potential risk of Parkinson's disease. Journal of Hazardous Materials, 2021, 412, 125230.	6.5	16
224	Acteoside exerts neuroprotection effects in the model of Parkinson's disease via inducing autophagy: Network pharmacology and experimental study. European Journal of Pharmacology, 2021, 903, 174136.	1.7	15
225	Gramine promotes functional recovery after spinal cord injury via ameliorating microglia activation. Journal of Cellular and Molecular Medicine, 2021, 25, 7980-7992.	1.6	7
226	Modulating Oxidative Stress Indices and Thiol-Disulfide Balance in the Brain Structures by Pantothenic Acid Derivatives in an Experimental Model of Parkinsonâ€™s Disease. Neurochemical Journal, 2021, 15, 24-29.	0.2	4
227	The Role of Free Radicals in the Nervous System. , 2011, , 1-17.		6
228	Behavioral Assessment in the African Green Monkey After MPTP Administration. Neuromethods, 2011, , 401-435.	0.2	6
229	Aetiopathogenesis. , 2014, , 57-81.		3
230	Common Pathways to Neurodegeneration and Co-morbid Depression. , 2010, , 185-241.		1
231	Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinsonâ€™s disease models. Aging, 2020, 12, 4641-4659.	1.4	100
232	Crosstalk between Ca2+ signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis. Oncotarget, 2016, 7, 7534-7549.	0.8	26
233	Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice. Central Nervous System Agents in Medicinal Chemistry, 2019, 19, 57-66.	0.5	10
234	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 251-270.	0.8	93
235	Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies. CNS and Neurological Disorders - Drug Targets, 2013, 12, 680-697.	0.8	29
236	Effect of treadmill exercise on catalepsy and the expression of the BDNF gene in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -induced Parkinson in male mice. Iranian Journal of Basic Medical Sciences, 2020, 23, 483-493.	1.0	2
237	Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice. Neural Regeneration Research, 2013, 8, 3275-83.	1.6	15
238	Assessment of DNA Damage in the Peripheral Lymphocytes of Patients with Parkinson's Disease and Multiple Sclerosis Using the Comet Assay. Turkiye Klinikleri Journal of Medical Sciences, 2013, 33, 936-945.	0.1	1
239	The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Reports, 2010, 43, 225-232.	1.1	134
240	PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model. BMB Reports, 2014, 47, 569-574.	1.1	28

#	Article	IF	Citations
241	Effects of bee venom and dopamine-loaded nanoparticles on reserpine-induced Parkinsonâ€™s disease rat model. Scientific Reports, 2021, 11, 21141.	1.6	8
242	Keeping it Together. Axonal Transport to the Synapse and the Effects of Molecular Chaperones in Health and Disease. , 2011, , 81-103.		0
244	Role of Microglia in Inflammatory Process in Parkinsonâ€™s Disease. , 0, , .		0
245	The neuroprotective effects of apocynin. Frontiers in Bioscience - Elite, 2012, E4, 2183.	0.9	31
246	Mortalin in Neurological Diseases. , 2012, , 139-158.		0
247	Medicinal Plants. , 2012, , 472-494.		0
248	Parkinsonâ€™s Disease: New Insights. Biochemistry & Pharmacology: Open Access, 2013, 02, .	0.2	0
249	Microglia: Neuroprotective and Neurodestructive Properties. , 2014, , 109-132.		2
250	The Role of Chronic Inflammation in the Etiology of Parkinsonâ€™s Disease. , 2016, , 63-74.		0
251	Evaluation of Apoptosis and Neuronal Changes in the Compact Part of Substantia Nigra and Striatum Following the Use of Levodopa and Levodopa -Benserazide in Parkinsonâ€™s Rats. Annals of Military and Health Sciences Research, 2018, In Press, .	0.1	0
252	PHYTOCHEMICALS AS FUTURE DRUGS FOR PARKINSONâ€™S DISEASE: A REVIEW. Plant Archives, 2020, 21, .	0.1	2
253	NF-Î²B in Aging and Disease. , 2011, 2, 449-65.		150
255	Monascin ameliorate inflammation in the lipopolysaccharide-induced BV-2 microglial cells via suppressing the NF-Î²B/p65 pathway. Iranian Journal of Basic Medical Sciences, 2020, 23, 461-468.	1.0	0
256	Freshwater Clam Extract Mitigates Neuroinflammation and Amplifies Neurotrophic Activity of Glia: Insights from In Vitro Model of Neurodegenerative Pathomechanism. Journal of Clinical Medicine, 2022, 11, 553.	1.0	0
257	Beneficial effects of linagliptin in cell culture model of Parkinsonâ€™s disease. The European Research Journal, 2022, 8, 242-246.	0.1	2
258	Erythropoietin and Bacillus Calmetteâ€“GuÃ©rin Vaccination Mitigate 3-Nitropropionic Acid-Induced Huntington-like Disease in Rats by Modulating the PI3K/Akt/mTOR/P70S6K Pathway and Enhancing the Autophagy. ACS Chemical Neuroscience, 2022, 13, 721-732.	1.7	16
259	Effects of Cannabis in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 495-508.	1.5	17
260	Increased risk of Parkinsonâ€™s disease among patients with age-related macular degeneration. BMC Ophthalmology, 2021, 21, 426.	0.6	11

#	Article	IF	Citations
261	Dietary fat intake and risk of Parkinson disease: results from the Swedish National March Cohort. European Journal of Epidemiology, 2022, 37, 603-613.	2.5	10
264	Potentiation of paraquat toxicity by inhibition of the antioxidant defenses and protective effect of the natural antioxidant, 4-hydroxyisopthalic acid in Drosophila melanogaster. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2022, , 109399.	1.3	0
265	Human gut microbiota and Parkinson's disease. Progress in Molecular Biology and Translational Science, 2022, , 281-307.	0.9	2
266	Cryptotanshinone protects against oxidative stress in the paraquatâ€induced Parkinson's disease model. Environmental Toxicology, 2023, 38, 39-48.	2.1	5
267	Xanthotoxin modulates oxidative stress, inflammation, and MAPK signaling in a rotenone-induced Parkinson's disease model. Life Sciences, 2022, 310, 121129.	2.0	7
268	Stem Cell Transplantation for Parkinsonâ€™s Disease: Current Challenges and Perspectives. , 2022, 13, 1652.		2
269	Protective Role of Quercetin Against Rotenone- Induced Hepato and Nephrotoxicity in Swiss Albino Mice. International Journal of Human Anatomy, 2021, 2, 8-27.	0.2	1
270	Newly Synthesized Creatine Derivatives as Potential Neuroprotective and Antioxidant Agents on In Vitro Models of Parkinsonâ€™s Disease. Life, 2023, 13, 139.	1.1	2
271	Nitric Oxide/Nitric Oxide Synthase System in the Pathogenesis of Neurodegenerative Disordersâ€”An Overview. Antioxidants, 2023, 12, 753.	2.2	10
272	Parkinsonâ€™s Disease Risk and Hyperhomocysteinemia: The Possible Link. Cellular and Molecular Neurobiology, 2023, 43, 2743-2759.	1.7	7
273	Multi-functional Ligands and Molecular Hybridization: Conceptual Aspects and Application in the Innovative Design of Drug Candidate Prototypes for Neurodegenerative Diseases. Frontiers in Clinical Drug Research CNS and Neurological Disorders, 2023, , 1-157.	0.1	0
275	Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. Neurochemical Research, 2023, 48, 3296-3315.	1.6	9
278	Nesfatin-1: A Biomarker and Potential Therapeutic Target in Neurological Disorders. Neurochemical Research, 0, , .	1.6	0